vs
豪洛捷（HOLX）与罗致恒富（RHI）财务数据对比。点击上方公司名可切换其他公司
罗致恒富的季度营收约是豪洛捷的1.2倍（$1.3B vs $1.0B），豪洛捷同比增速更快（2.5% vs -5.8%），豪洛捷自由现金流更多（$215.2M vs $170.8M），过去两年豪洛捷的营收复合增速更高（1.5% vs -6.1%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
罗致恒富是1948年成立的国际人力资源咨询机构，总部位于加利福尼亚州门洛帕克和圣拉蒙，是全球规模领先的会计与金融领域人才派遣服务商之一，在全球范围内设有超过345个办公点。
HOLX vs RHI — 直观对比
营收规模更大
RHI
是对方的1.2倍
$1.0B
营收增速更快
HOLX
高出8.3%
-5.8%
自由现金流更多
HOLX
多$44.4M
$170.8M
两年增速更快
HOLX
近两年复合增速
-6.1%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $1.3B |
| 净利润 | $179.1M | — |
| 毛利率 | 56.0% | 37.6% |
| 营业利润率 | 22.6% | 1.7% |
| 净利率 | 17.1% | — |
| 营收同比 | 2.5% | -5.8% |
| 净利润同比 | -10.9% | — |
| 每股收益（稀释后） | $0.79 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXRHI
| Q4 25 | $1.0B | $1.3B | ||
| Q3 25 | $1.0B | $1.4B | ||
| Q2 25 | $1.0B | $1.4B | ||
| Q1 25 | $1.0B | $1.4B | ||
| Q4 24 | $1.0B | $1.4B | ||
| Q3 24 | $988.0M | $1.5B | ||
| Q2 24 | $1.0B | $1.5B | ||
| Q1 24 | $1.0B | $1.5B |
净利润HOLXRHI
| Q4 25 | $179.1M | — | ||
| Q3 25 | $187.2M | $42.9M | ||
| Q2 25 | $194.9M | $41.0M | ||
| Q1 25 | $-17.4M | $17.4M | ||
| Q4 24 | $201.0M | — | ||
| Q3 24 | $178.6M | $65.5M | ||
| Q2 24 | $194.5M | $68.2M | ||
| Q1 24 | $169.9M | $63.7M |
毛利率HOLXRHI
| Q4 25 | 56.0% | 37.6% | ||
| Q3 25 | 55.6% | 37.2% | ||
| Q2 25 | 56.3% | 37.2% | ||
| Q1 25 | 37.5% | 36.9% | ||
| Q4 24 | 56.8% | 38.8% | ||
| Q3 24 | 56.4% | 39.0% | ||
| Q2 24 | 55.4% | 39.2% | ||
| Q1 24 | 53.3% | 38.1% |
营业利润率HOLXRHI
| Q4 25 | 22.6% | 1.7% | ||
| Q3 25 | 22.6% | 1.0% | ||
| Q2 25 | 24.9% | 0.1% | ||
| Q1 25 | -0.7% | 2.9% | ||
| Q4 24 | 22.5% | 4.7% | ||
| Q3 24 | 23.3% | 4.1% | ||
| Q2 24 | 24.1% | 5.1% | ||
| Q1 24 | 20.7% | 2.8% |
净利率HOLXRHI
| Q4 25 | 17.1% | — | ||
| Q3 25 | 17.8% | 3.2% | ||
| Q2 25 | 19.0% | 3.0% | ||
| Q1 25 | -1.7% | 1.3% | ||
| Q4 24 | 19.7% | — | ||
| Q3 24 | 18.1% | 4.5% | ||
| Q2 24 | 19.2% | 4.6% | ||
| Q1 24 | 16.7% | 4.3% |
每股收益（稀释后）HOLXRHI
| Q4 25 | $0.79 | $0.32 | ||
| Q3 25 | $0.84 | $0.43 | ||
| Q2 25 | $0.86 | $0.41 | ||
| Q1 25 | $-0.08 | $0.17 | ||
| Q4 24 | $0.87 | $0.53 | ||
| Q3 24 | $0.75 | $0.64 | ||
| Q2 24 | $0.82 | $0.66 | ||
| Q1 24 | $0.72 | $0.61 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $464.4M |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $5.2B | $1.3B |
| 总资产 | $9.2B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.48× | — |
8季度趋势，按日历期对齐
现金及短期投资HOLXRHI
| Q4 25 | $2.4B | $464.4M | ||
| Q3 25 | $2.2B | $365.3M | ||
| Q2 25 | $1.9B | $380.5M | ||
| Q1 25 | $1.6B | $342.5M | ||
| Q4 24 | $2.0B | $537.6M | ||
| Q3 24 | $2.3B | $570.5M | ||
| Q2 24 | $2.4B | $547.4M | ||
| Q1 24 | $2.2B | $540.9M |
总债务HOLXRHI
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
股东权益HOLXRHI
| Q4 25 | $5.2B | $1.3B | ||
| Q3 25 | $5.0B | $1.3B | ||
| Q2 25 | $4.8B | $1.3B | ||
| Q1 25 | $4.6B | $1.3B | ||
| Q4 24 | $4.8B | $1.4B | ||
| Q3 24 | $5.1B | $1.5B | ||
| Q2 24 | $5.0B | $1.5B | ||
| Q1 24 | $4.8B | $1.5B |
总资产HOLXRHI
| Q4 25 | $9.2B | $2.9B | ||
| Q3 25 | $9.0B | $2.8B | ||
| Q2 25 | $8.8B | $2.8B | ||
| Q1 25 | $8.5B | $2.7B | ||
| Q4 24 | $8.7B | $2.9B | ||
| Q3 24 | $9.2B | $3.0B | ||
| Q2 24 | $8.9B | $2.9B | ||
| Q1 24 | $8.7B | $2.9B |
负债/权益比HOLXRHI
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | $182.5M |
| 自由现金流经营现金流 - 资本支出 | $215.2M | $170.8M |
| 自由现金流率自由现金流/营收 | 20.5% | 13.1% |
| 资本支出强度资本支出/营收 | 1.4% | 0.9% |
| 现金转化率经营现金流/净利润 | 1.28× | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | $266.8M |
8季度趋势，按日历期对齐
经营现金流HOLXRHI
| Q4 25 | $229.9M | $182.5M | ||
| Q3 25 | $355.1M | $77.4M | ||
| Q2 25 | $343.3M | $119.4M | ||
| Q1 25 | $169.4M | $-59.3M | ||
| Q4 24 | $189.3M | $154.8M | ||
| Q3 24 | $367.0M | $129.6M | ||
| Q2 24 | $405.8M | $142.0M | ||
| Q1 24 | $292.4M | $-15.9M |
自由现金流HOLXRHI
| Q4 25 | $215.2M | $170.8M | ||
| Q3 25 | $341.4M | $63.6M | ||
| Q2 25 | $330.5M | $104.2M | ||
| Q1 25 | $153.9M | $-71.7M | ||
| Q4 24 | $172.5M | $140.5M | ||
| Q3 24 | $350.6M | $111.8M | ||
| Q2 24 | $385.3M | $129.6M | ||
| Q1 24 | $279.6M | $-27.7M |
自由现金流率HOLXRHI
| Q4 25 | 20.5% | 13.1% | ||
| Q3 25 | 32.5% | 4.7% | ||
| Q2 25 | 32.3% | 7.6% | ||
| Q1 25 | 15.3% | -5.3% | ||
| Q4 24 | 16.9% | 10.2% | ||
| Q3 24 | 35.5% | 7.6% | ||
| Q2 24 | 38.1% | 8.8% | ||
| Q1 24 | 27.5% | -1.9% |
资本支出强度HOLXRHI
| Q4 25 | 1.4% | 0.9% | ||
| Q3 25 | 1.3% | 1.0% | ||
| Q2 25 | 1.3% | 1.1% | ||
| Q1 25 | 1.5% | 0.9% | ||
| Q4 24 | 1.6% | 1.0% | ||
| Q3 24 | 1.7% | 1.2% | ||
| Q2 24 | 2.0% | 0.8% | ||
| Q1 24 | 1.3% | 0.8% |
现金转化率HOLXRHI
| Q4 25 | 1.28× | — | ||
| Q3 25 | 1.90× | 1.80× | ||
| Q2 25 | 1.76× | 2.91× | ||
| Q1 25 | — | -3.42× | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | 1.98× | ||
| Q2 24 | 2.09× | 2.08× | ||
| Q1 24 | 1.72× | -0.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
RHI
| Finance And Accounting | $535.2M | 41% |
| Protiviti | $479.0M | 37% |
| Technology | $156.4M | 12% |
| Permanent Placement Talent Solutions | $102.6M | 8% |
| Other | $29.2M | 2% |
